Breast Biopsy Market

Market Overview

The global Breast Biopsy Market size was valued at USD 2.15 billion in 2023, and is predicted to reach USD 3.78 billion by 2030, with a CAGR of 8.5% from 2024 to 2030. Breast biopsy is a medical technique of collecting specimen samples of breast tissue or fluid to diagnose breast cancer and other diseases through laboratory testing. This technique is performed when symptoms such as a breast lump, sore breast, breast dimpling, peeling of the breast, and nipple discharge are identified. 

Breast biopsy is performed through surgically or minimally invasive techniques by a radiologist. Various types of breast biopsy include fine-needle aspiration biopsy, core needle biopsy, and stereotactic biopsy. In addition, other techniques related to breast biopsies are carried out under ultrasound, MRI, or stereotactic. Breast biopsy is generally performed after a suspicious lesion is diagnosed in other mammography or ultrasound. Then tissues are sent for pathological findings.      

Market Dynamics and Trends

The demand for breast biopsy is rising due to increase in the number of breast cancer cases across the world. For instance, in 2020, there were 2.3 million women diagnosed with breast cancer and nearly 685,000 deaths reported globally. Also, latest advancements in 3D scanning technologies such as 3D mammography and 3D metabolic imaging to detect metabolic activity in the breast in women are expected to further propel the breast biopsy market. Moreover, increasing awareness about breast cancer is leading to the increased funding for research projects to develop appropriate diagnostics and alternatives. 

For instance, in 2020, the National Cancer Institute (NIA) allocated the amount of USD 514.7 million as a fund for diagnosis and treatment of breast cancer. Also, in October 2021, Goa Government launched an initiative for free breast cancer screening for one lakh women under the initiative ‘Swasth Mahila, Swasth Goa (Healthy Women, Healthy Goa)’. This is further expected to drive the growth of breast biopsy market during the forecast period.

However, risks and ill-effects related to breast biopsy such as swelling, bruising, soreness, and post-surgery infection are the factors that are expected to restrain the growth of the market during the forecast period. On the contrary, development of new technologies such as vacuum-assisted biopsy, image-guided biopsy, liquid biopsy, and promising clinical trials are expected to create ample opportunities for the market in the coming years.

Market Segmentations and Scope of the Study

The breast biopsy market is segmented on the basis of type, product, guidance, application, and geography. On the basis of type, the market is bifurcated into needle breast biopsy, open surgical breast biopsy, and liquid breast biopsy. On the basis of product, the market is classified into biopsy needles, biopsy tables, localization wires, guidance systems, assay kit, liquid biopsy instruments, and others. On the basis of guidance, the market is categorized into image guided biopsy and liquid biopsy.  On the basis of application, the market is segmented into early cancer screening, therapy selection, treatment monitoring, and recurrence monitoring. The geographical breakdown and analysis of each of the aforesaid segments include regions such as North America, Europe, Asia-Pacific, and RoW.

Geographical Analysis

North America holds the lion’s share of the breast biopsy market, and is expected to continue its dominance during the forecast period. This is attributed to the advantages of needle-based biopsy. This type of biopsy obtains a small portion of tissue, and multiple samples can be collected through a single-entry site. Also, rapidly growing demand for minimally invasive procedures such as stereotactic, a procedure that utilizes mammography to precisely identify and carry out biopsy of an abnormality within the breast, drives the market growth in this region. 

Moreover, rising awareness of palpable lumps in breasts at the early stage and on-time treatment is expected to impact the breast biopsy market growth in this region.
On the other hand, Asia-Pacific is expected to show a steady rise in the breast biopsy market, due to the development of healthcare infrastructure in emerging economies such as China, India, and South Korea. In addition, the adoption of advanced techniques such as polymerase chain reaction (PR) and next-generation sequencing (NGS) that identify genomic mutations in a tumor's genes drives the growth in this region. 

Also, increase in breast cancer screening programs by non-governmental organizations (NGOs) is expected to drive the breast biopsy market growth in this region. For instance, in February 2022, PoornaSudha Cancer Foundation conducted a mobile mammography unit on Richmond Road in a bus parked in Banashankari. The NGO conducts breast cancer screening camps for women. The NGO does not charge any fees for testing and screening. However, it only charges for transport.

Competitive Landscape

Various market players operating in the beast biopsy market include Epic Sciences, F. Hoffmann-La Roche AG, Bio-Rad Laboratories, Inc., Janssen Diagnostics, Biocept, Inc., Guardant Health, Inc., Myriad Genetics, Adaptive Biotechnologies, Fluxion Biosciences, Inc., and Biodesix. These market players are adopting various strategies such as collaborations and innovations across various regions to maintain their dominance in the breast biopsy market. 

For instance, in February 2022, Epic Sciences announced the collaboration with Fulgent Genetics to deliver promising results with its DefineMBC test. It includes cell-based and cell-free analysis to provide comprehensive MBC profiling when a tissue biopsy result is not available for patients. Additionally, in December 2021, F. Hoffmann-La Roche AG announced the release of its artificial intelligence (AI)-based digital pathology algorithms to aid pathologists in image analysis, accurate detection, classification, and prediction of patients with breast cancer.

Key Benefits

• The breast biopsy market report provides the quantitative analysis of the current market and estimations from 2022 to 2030. This analysis assists in identifying the prevailing market opportunities to capitalize on.

• The study comprises of a detailed analysis of the breast biopsy market trends including the current and future trends for depicting the prevalent investment pockets in the market.

• The information related to key drivers, restraints, and opportunities and their impact on the breast biopsy market is provided in the report.

• The competitive analysis of the market players along with their market share in the breast biopsy market is mentioned.

• The SWOT analysis and Porter’s Five Forces model are elaborated in the study.

• The value chain analysis in the market study provides a clear picture of the stakeholders’ roles.

Key Market Segments

By Type

• Needle Breast Biopsy

  • Core Needle Biopsy (CNB)

  • Fine Needle Aspiration Biopsy (FNAB)

  • Vacuum-assisted Biopsy (VAB)

• Open Surgical Breast Biopsy

  • Excisional

  • Incisional

• Liquid Breast Biopsy

  • Circulating Tumor Cells

  • Circulating Tumor DNA (CtDNA)

  • Other Biomarkers

By Product

• Biopsy Needles

• Biopsy Tables

• Localization Wires

• Guidance Systems

• Assay Kits

• Liquid Biopsy Instruments

• Others

By Guidance

• Image-Guided Biopsy

  • Mammography-guided Stereotactic Biopsy

  • Ultrasound-guided Biopsy

  • MRI-guided Biopsy

  • Other Guidance Techniques

• Liquid Biopsy

  • NGS-based Biopsy

  • PCR-based Biopsy

  • Microarray-based Biopsy

By Application

• Early Cancer Screening

• Therapy Selection

• Treatment Monitoring

• Recurrence Monitoring

By Geography

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • U.K.

  • Germany

  • Italy

  • Spain

  • Netherlands

  • Rest of Europe

• Asia-Pacific

  • China

  • India

  • Japan

  • South Korea

  • Australia

  • Taiwan

  • Vietnam

  • Rest of Asia-Pacific

• RoW

  • Latin America

  • Middle East

  • Africa

KEY PLAYERS

• Epic Sciences

• F. Hoffmann-La Roche AG

• Bio-Rad Laboratories, Inc.

• Janssen Diagnostics

• Biocept, Inc.

• Guardant Health, Inc.

• Myriad Genetics

• Adaptive Biotechnologies

• Fluxion Biosciences, Inc.

• Biodesix

REPORT SCOPE AND SEGMENTATION:

Parameters	Details
Analysis Period	2021–2030
Base Year Considered	2021
Forecast Period	2022–2030
Market Size Estimation	billion (USD)
Market Segmentation	By Type (Needle Biopsy (CNB, FNAB, VAB), Liquid Biopsy (CTC, ctDNA)), by Product (Needles, Tables, Assay Kit), by Guidance (Image-Guided (Mammography, Ultrasound, MRI), Liquid Biopsy (NGS, PCR, Microarray-based)) and by Application (Early Cancer Screening, Therapy Selection, Treatment Monitoring, Recurrence Monitoring)
Geographical Segmentation	North America (U.S., Canada, Mexico) Europe (U.K., Germany, Italy, Spain, Netherlands, Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Australia, Taiwan, Vietnam, Rest of Asia-Pacific), Rest of the World (Latin America, Middle East, Africa)
Companies Profiled	Epic Sciences, F. Hoffmann-La Roche AG, Bio-Rad Laboratories, Inc., Janssen Diagnostics, Biocept, Inc., Guardant Health, Inc., Myriad Genetics, Adaptive Biotechnologies, Fluxion Biosciences, Inc., and Biodesix.